U.S. market Closed. Opens in 5 hours 10 minutes

BTAI | BioXcel Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for BTAI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is bad and Health is frighteningly weak.

Valuation (5%)

Company Industry
P/E Ratio (TTM) -0.23 -22.37
PEG Ratio (TTM) -0.01 15.65
P/S Ratio (TTM) 10.35 49.21
P/B Ratio (TTM) -0.33 18.45
P/FCF Ratio (TTM) -0.24 -1.64
Price to 5YR AVG Earnings Ratio -0.14 -2.80
Price to 5YR AVG FCF Ratio -0.27 -8.54

Profitability (50%)

Company Industry
ROA (TTM) -164.79% -4.65%
ROE (TTM) 176.93% 20.33%
Net Profit Margin (TTM) -4,487.39% -1,544.80%
ROIC 5YR AVG 880.46% 16.10%

Growth (42%)

4QTR AVG 3YR AVG 5YR AVG
EPS 30.80% -49.20% -39.93%
Revenue 32.34% N/A 53.60%
Net Income 27.56% -83.82% -63.36%
Cash Flow 8.34% -89.66% -69.65%

Health (25%)

Company Industry
Current Ratio (TTM) 2.35 6.09
Quick Ratio (TTM) 2.25 5.81
D/E Ratio (TTM) -1.39 -16.41
Interest Coverage (TTM) -7.72 -0.80
Piotroski F-Score 2 5
Altman Z-Score N/A 13.80
LTL to 5YR AVG FCF -1.07 0.17
Shares Outstanding Growth 5YR AVG 15.35% 128.83%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙